Adverum Biotechnologies Inc (NASDAQ:ADVM) has a beta value of 1.16 and has seen 82462.0 shares traded in the last trading session. The company, currently valued at $92.77M, closed the last trade at $4.46 per share which meant it gained $0.17 on the day or 3.96% during that session. The ADVM stock price is -453.81% off its 52-week high price of $24.70 and 13.68% above the 52-week low of $3.85. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.15 million shares traded. The 3-month trading volume is 222.80K shares.
The consensus among analysts is that Adverum Biotechnologies Inc (ADVM) is Buy stock at the moment, with a recommendation rating of 1.25. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 2 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.38.
Adverum Biotechnologies Inc (NASDAQ:ADVM) trade information
Sporting 3.96% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ADVM stock price touched $4.46 or saw a rise of 9.53%. Year-to-date, Adverum Biotechnologies Inc shares have moved -4.50%, while the 5-day performance has seen it change 3.72%. Over the past 30 days, the shares of Adverum Biotechnologies Inc (NASDAQ:ADVM) have changed -4.29%. Short interest in the company has seen 1.42 million shares shorted with days to cover at 8.11.
Wall Street analysts have a consensus price target for the stock at $20, which means that the shares’ value could jump 77.7% from current levels. The projected low price target is $10.0 while the price target rests at a high of $28.0. In that case, then, we find that the current price level is -527.8% off the targeted high while a plunge would see the stock gain -124.22% from current levels.
Adverum Biotechnologies Inc (ADVM) estimates and forecasts
The company’s shares have lost -30.85% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -72.22%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 0.36% over the past 5 years. Earnings growth for 2025 is a modest 56.78% while over the next 5 years, the company’s earnings are expected to increase by 28.94%.
ADVM Dividends
Adverum Biotechnologies Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adverum Biotechnologies Inc (NASDAQ:ADVM)’s Major holders
Insiders own 12.51% of the company shares, while shares held by institutions stand at 74.85% with a share float percentage of 85.56%. Investors are also buoyed by the number of investors in a company, with Adverum Biotechnologies Inc having a total of 104.0 institutions that hold shares in the company. The top two institutional holders are TCG CROSSOVER MANAGEMENT, LLC with over 2.01 million shares worth more than $13.78 million. As of 2024-06-30, TCG CROSSOVER MANAGEMENT, LLC held 12.1873% of shares outstanding.
The other major institutional holder is VERSANT VENTURE MANAGEMENT, LLC, with the holding of over 0.51 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.48 million and represent 3.0756% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Franklin Strategic Series-Franklin Biotechnology Discove and iShares Russell 2000 ETF. As of Oct 31, 2024, the former fund manager holds about 3.00% shares in the company for having 624.74 shares of worth $2.79 million while later fund manager owns 589.5 shares of worth $2.63 million as of Nov 30, 2024, which makes it owner of about 2.83% of company’s outstanding stock.
